Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 6/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.50 |
| ▸ | POLA1 | P09884 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HBB | P68871 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1152839 | 1.00 | SLC29A1 (0.51) | SLC29A1ADRB1DNMT1POLA1CYP1A2 | |
| SCHEMBL5067228 | 0.80 | DNMT1 (0.53) | SLC29A1ADRB1DNMT1CYP1A2HBB | |
| SCHEMBL14089974 | 0.80 | DNMT1 (0.57) | ADRB1DNMT1 | |
| SCHEMBL8723517 | 0.77 | SLC29A1 (0.44) | SLC29A1POLA1CYP1A2HBBTYMS | |
| SCHEMBL23371941 | 0.76 | DNMT1 (0.59) | ADRB1DNMT1 | |
| SCHEMBL8595980 | 0.76 | SLC29A1 (0.59) | SLC29A1ADRB1DNMT1POLA1CYP1A2 | |
| SCHEMBL7646628 | 0.74 | POLB (0.51) | SLC29A1ADRB1DNMT1TYMS | |
| SCHEMBL8712084 | 0.74 | POLB (0.46) | SLC29A1 | |
| SCHEMBL8712086 | 0.74 | POLB (0.46) | SLC29A1 | |
| SCHEMBL14089492 | 0.73 | ADRB1 (0.46) | ADRB1DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310479-A1 | LOW DOSE ADJUVANT EPIGENETIC CANCER THERAPY | UNIV JOHNS HOPKINS (US) | 2023-10-05 | — | — | US | claimed |
| WO-2021081481-A1 | LOW DOSE ADJUVANT EPIGENETIC CANCER THERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-04-29 | — | — | WO | claimed |
| US-20140171492-A1 | CHIMERIC RNA OLIGONUCLEOTIDES AND USES THEREOF | UNIVERSITA CATTOLICA DEL SACRO CUORE (IT) | 2014-06-19 | — | — | US | claimed |
| WO-2012142480-A1 | CHIMERIC RNA OLIGONUCLEOTIDES AND USES THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2012-10-18 | — | — | WO | claimed |
| WO-2008054767-A9 | N4 MODIFICATIONS OF PYRIMIDINE ANALOGS AND USES THEREOF | UNIV SOUTHERN CALIFORNIA (US) | 2008-12-31 | — | — | WO | claimed |
| US-20080234223-A1 | N4 MODIFICATIONS OF PYRIMIDINE ANALOGS AND USES THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2008-09-25 | — | — | US | claimed |
| WO-2008054767-A2 | N4 MODIFICATIONS OF PYRIMIDINE ANALOGS AND USES THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2008-05-08 | — | — | WO | claimed |
| US-20230310479-A1 | LOW DOSE ADJUVANT EPIGENETIC CANCER THERAPY | UNIV JOHNS HOPKINS (US) | 2023-10-05 | — | — | US | disclosed |
| WO-2021081481-A1 | LOW DOSE ADJUVANT EPIGENETIC CANCER THERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-04-29 | — | — | WO | disclosed |
| US-10941399-B2 | Methods and compositions for gene-specific demethylation by DNA methyltransferase (DNMT)-RNA interaction | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20140171492-A1 | CHIMERIC RNA OLIGONUCLEOTIDES AND USES THEREOF | UNIVERSITA CATTOLICA DEL SACRO CUORE (IT) | 2014-06-19 | — | — | US | disclosed |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| WO-2012142480-A1 | CHIMERIC RNA OLIGONUCLEOTIDES AND USES THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2012-10-18 | — | — | WO | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| WO-2008054767-A9 | N4 MODIFICATIONS OF PYRIMIDINE ANALOGS AND USES THEREOF | UNIV SOUTHERN CALIFORNIA (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20080234223-A1 | N4 MODIFICATIONS OF PYRIMIDINE ANALOGS AND USES THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234223-A1 | N4 MODIFICATIONS OF PYRIMIDINE ANALOGS AND USES THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2008-09-25 | — | — | US | disclosed |
| WO-2008054767-A2 | N4 MODIFICATIONS OF PYRIMIDINE ANALOGS AND USES THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234223-A1 | N4 MODIFICATIONS OF PYRIMIDINE ANALOGS AND USES THEREOF | TYMP, TYMS, DPYD | SLC29A1 15/4885ADRB1 4599/4885DNMT1 465/4885 |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | SLC29A1 2545/4885ADRB1 2147/4885DNMT1 2586/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | SLC29A1 2545/4885ADRB1 2147/4885DNMT1 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.